U.S. Microfluidics Market

U.S. Microfluidics Market Size (2023 to 2028)

The size of the microfluidics market in the United States is predicted to grow at a healthy CAGR during the forecast period.

The United States Microfluidics market is projected to be driven by factors such as a growing focus on data precision and accuracy, rising research and development activities, and the demand for point of care. Microfluidics-based technological advancements such as organ-on-chip and evolving drug delivery applications are expected to fuel the U.S. microfluidics market growth. On the other hand, the prevalence of chronic diseases, the geriatric population, and rising per capita income drive the acceptance of microfluidics in diagnosis, which is projected to boost the market growth. Also, Microfluidics technologies such as sample infection in mass spectrometry, immunoassays, flow cytometry capillary electrophoresis, and PCR Amplification are employed. However, increasing investment and funding by private and government organizations encourages market growth. Besides, a rise in the need for low-volume sample analysis and evolving 3D technology is expected to drive the U.S. microfluidics market during the forecast period. 

Other factors such as Point-of-testing and innovations in microfluidics products are significant factors for promoting a large share to the U.S. microfluidics market. The United States is providing significant growth opportunities for the market players, which is expected to increase the market growth. The rising adoption of technological advancements in emerging cities and viable commercial technologies are projected to increase market growth. Further, government favorable reimbursement programs and initiatives enhance the better market growth in the united states over the forecast period.

The key restraints for commercial development are integrating microfluidics technologies into current processes necessitates a significant investment, putting an added burden on healthcare practitioners. The presence of complicated and time-consuming regulatory requirements and a lack of knowledge about microfluidics are factors limiting the growth of the U.S. microfluidics market.

Impact on COVID-19 on the U.S. microfluidics market:

A large number of COVID-19 cases are testing, which puts the burden on the laboratories. Rapid detection can reduce the number of unnecessary visits to the health clinics and help the health sector save lives by treating patients with positive test results. Microfluidics is the scientific research of manipulating minimal amounts of fluid in micron-scale channels and chambers. Hence, it will allow researchers to handle fewer samples and reagents with higher efficiencies and generate results faster than conventional methods, owing to the high potentials of microfluidic technology. Evaluation of current diagnostic methods for COVID-19 states that biosensor-based virus detection systems that utilize nanotechnology and microfluidics and instrumental advances are considered promising technologies in pandemic situations like COVID-19.

This research report on the U.S. microfluidics market has been segmented & sub-segmented into the following categories.

By Product:

• Microfluidic devices
• Microfluidic components

By Industry:

• In-vitro diagnostics
• Pharmaceutical
• Medical devices
• Others

By Material:

• Polymer
• Glass
• Silicon
• Others

By Application:

• Lab-on-a-chip
• Organs-on-chips
• Continuous flow
• Optofluidics
• Acoustofluidics
• Electrophoresis

By Country:

• The United States

The United States microfluidics market is forecasted to play a dominating role in the North American market during the forecast period. Rising technological advancements are the major driving factors driving the microfluidic device market in the U.S. Also, the growing demand for point-of-care testing in the country strongly impacts market growth. However, in recent years, diagnostics companies such as Abbott Point of Care, Alere, BD Diagnostics, Cepheid, and Abaxis have recognized the promise of rapid molecular diagnostic testing and introduced many promising point-of-care products focused on microfluidic technology. The research institutes in the U.S. play an active role in the manufacture of novel microfluidic instruments, which is expected to boost the market growth. Increasing focus of stakeholders on reports on research projects involving proteins, genes, and associated biomolecules create the market.

KEY MARKET PARTICIPANTS:

Some of the prominent companies operating in the U.S. microfluidics market profiled in this report are Parker-Hannifin Corporation, SMC Corporation, Idex Corporation, Fluigent SA, Dolomite Microfluidics, Aignep S.P.A., Camozzi Automation Spa Società Unipersonale, Elveflow, Cellix Ltd., Fortive Corporation, Danaher Corporation, Thermo Fisher Scientific Inc., Perkinelmer, Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Becton, Dickinson And Company, Illumina, Inc., F. Hoffmann-La Roche Ltd., Fluidigm Corporation and Abbott Laboratories.